The historic rise of Viagra has long been a benchmark of pharmaceutical success, but its future within the broader sector now triggers questions about potential gains. Alternative versions are eroding patent protection , prompting anxieties that investing in companies significantly dependent to Viagra's former position could be a speculative decisi